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INTRODUCTION
This study was funded to assess the relationship of RhoC and NF-kappa B to aggressive, metastatic, and therapy-resistant breast cancer. Inflammation is currently being considered a key component of cancer initiation and progression. [1] Many proinflammatory stimuli act through an NF-kappa B dependent signaling pathway. It is likely that RhoC, which is recognized as an important marker of breast cancer, aggressiveness is also regulated by NF-kappa B.
The tumor microenvironment is exceptionally critical in our understanding of cancer development. Recent research suggests that chronic inflammation is triggered during tumor growth. The tumor associated inflammation contributes greatly to the tumor microenvironment and perhaps even to tumor macroenvironment. Tumor-associated macrophages (TAMs) secrete numerous signaling molecules that interact with tumor and stromal cells. Secretion of TNF-α by TAMs activates NF-kappa B within the tumor cell through the receptor tyrosine kinase pathway.
Rho-GTPases are members of the Ras-superfamily. Activation of Rho promotes both the bundling of actin filaments with myosin II filaments into stress fibers and the clustering of integrins and associated proteins to form focal contacts. [2] Experiments conducted within the Merajver laboratory have shown an active role for RhoC in rearrangement of the cytoskeleton in cell motility and invasion.
We hypothesize that NF-kappa B is a transcription factor for the RhoC gene and leads to overexpression of cellular RhoC protein. As more is learned about these tumor markers, the potential exists for improved clinical diagnosis, prognosis, and treatment. The purpose of the study is to understand the regulation of RhoC gene expression in an epidemiological setting. A clear understanding of the genetic and cellular mechanisms involved in modulating a highly metastatic phenotype is expected to aid in diagnosis and treatment.
The scope of this work includes the identification and collection of patient information from Henry Ford Health system (HFHS). HFHS is an integrated health system that offers a diverse, population-based patient population from which strong epidemiologic studies can be built. Patient information, including diagnostic and recurrence data, will be combined with gene expression data. Molecular and statistical analysis will occur in collaboration with the University of Michigan.
BODY
In the second 12 months of the project, we projected that we would conduct the study tumor microarray analyses. Below are the objectives from the original statement of work.
Task 3.
To conduct tumor microarray analyses a. Write laboratory procedures manual b. Prepare TMA c. Interpret and quantify TMA results d. Enter laboratory data results into database Hensley Alford, S Award #W81XWH-04-1-0395
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The complete dataset (abstracted medical record data with TMA data) is expect to be established within the next 6 months. At that time we will be able to begin the analysis of the data for key results. Although case identification and key patient level information had already been collected, it was decided that the time and effort was available to conduct a more systematic medical record abstraction. A formal data collection codebook (Appendix A) and data collection instrument (Appendix B) were developed. The data collection instrument was developed into an ACCESS database form to which TMA can be easily and efficiently added. In addition, it was decided after biostatistical consult to expand the years of patient accrual as well as the eligible tumor stages. This will ensure that adequate power is available for the final analyses.
Other research activities, supported in part by funding from this grant, have included working with population data for the Arab-American community in Detroit. Arab women have been reported to have an increased incidence of inflammatory breast cancer (IBC), a particularly aggressive form of breast cancer. RhoC has been shown to be amplified in inflammatory breast cancer and may likely be the key to IBC's aggressive phenotype.
[3] Ms. Alford presented a poster on breast cancer in Arab-American women during the 2005 San Antonio Breast Cancer Symposium.
[4] This poster presentation was also given at the Henry Ford Health System Annual Research Symposium where it was selected as a winner.
KEY RESEARCH ACCOMPLISHMENTS
• Development of data collection instrument and codebook • Creation of an ACCESS form for data entry • Expansion of study sample
REPORTABLE OUTCOMES
Reportable outcomes are expected for the next review.
CONCLUSIONS
Exciting research has surfaced in the past year regarding the tumor microenvironment and breast cancer metastasis. Areas which our genes of interest are likely to play a significant role. Despite this, no one else is currently investigating our genes of interest and their role in an aggressive breast cancer phenotype. As clinical oncology looks more to targeted therapy for treatment options, our work will hopefully be able to provide valuable insight for drug development. If the primary breast cancer diagnosis was an invasive malignancy enter code 01 and go to E1.3.
E1.Eligibility Information

E1.1 Date of Diagnosis
If the primary breast cancer diagnosis was not an invasive malignancy enter code 02. Patient is ineligible -end of data collection.
If the primary breast cancer diagnosis is unknown enter code 09. These cases will be reviewed. The five-digit identification number.
E1.3 Cancer laterality
SOURCE DOCUMENT:
The identification number is assigned, use the patient list.
CODE RANGE:
The digits are a unique random number.
DIRECTIVES:
Required. This field should never be left blank and is recorded on each sheet. Record the history of any prior cancers and specify the cancers in the space provided. Non-melanoma skin cancers do not need to be recorded and if the patient has a history of a prior breast cancer then she is ineligible.
Date of Birth
Personal History
Medical History
Cardiovascular diseases of interest include heart disease, cerebrovascular disease, hypertension, and hypercholesterolemia. If patient has a history of DCIS and/or LCIS prior to their invasive diagnosis, then circle the "X" associated with the diagnosis. If no history is noted then circle the "X" for the "No".
Family History
Record in the same manner for DCIS and/or LCIS noted at the time of diagnosis.
If patient has a diagnosis of LCIS and/or DCIS following the invasive diagnosis but prior to a recurrent invasive diagnosis then note in 2.3.3. If patient is divorced or widowed at the time of diagnosis code 02.
Smoking Status
If patient is separated, single or has never been married then code 03.
If there is no mention in the medical record then code 04.
Gravidity
DATA ELEMENT: Gravidity
DEFINITION:
Number of times patient has been pregnant.
SOURCE DOCUMENT:
Medical record CODE RANGE: 00-99
DIRECTIVES:
If the patient has never been pregnant then code 00.
If the patient has been pregnant then use a two digit code to record the number of pregnancies.
If there is no mention of the patient's pregnancy history then code 99. If the patient has never had a live birth then code 00.
Parity
If the patient has had at least one live birth then use a two digit code to record the number of live births.
If there is no mention of the number of live births then code 99. If the patient is currently perimenopausal then enter 01.
Age of first pregnancy
If the patient has experienced menopause then enter a two digit code for the patient's age at menopause. If the patient has a history of or is currently taking hormone replacement therapy then code 01.
Type of menopause
If the patient has never taken hormone replacement therapy then code 02.
If there is no mention of the patient's history of hormone replacement therapy then code 03. If no primary tumor, record "000.00".
History of oral contraceptives
The hierarchy for sources for tumor size information is the following: 1) pathology report, 2) operative report, 3) physical examination and 4) mammography. Read the entire pathology report before recording any tumor size. Record the tumor size reported in the "Summary" or "Diagnosis" section of a pathology report or other record in preference to other measurements. When no tumor size is reported in such a section, record the tumor size reported in the gross pathology section in preference to the tumor size reported in the microscopic pathology section. If the microscopic section contains the only tumor size report, then use the microscopic measurement. Code the tumor size before any neoadjuvant therapy (radiation, chemotherapy, hormonal therapy or immunotherapy). If there was neoadjuvant therapy then you will need to record the clinical or mammographic tumor size. You may also need to modify the tumor size reported in the summary or gross section of the report if the microscopic report indicates that the tumor contains ductal carcinoma in situ and that indication is not reflected in the tumor size reported in the summary or gross section (i.e., if the tumor size reflects more than just the invasive component --see below).
Exclude measurements of ductal carcinoma in situ from the total tumor size measurement. The microscopic section of the pathology report may indicate that the total tumor size includes a DCIS component, in which case the tumor size should be reduced by the largest DCIS dimension or multiplied by (1-fraction DCIS). For example, a 1 cm tumor that includes 0.2 cm DCIS, or is reported as 20% DCIS, should be recorded as 0.8 cm diameter.
If more than one dimension is given for a tumor or piece of a tumor, record the largest dimension.
If there is more than one piece of the tumor, add the largest dimensions of all the pieces.
If there is more than one tumor, record the size for the largest tumor (including adding its pieces as described above).
Tumor size should be recorded from the procedure that reports the largest tumor when all of the pieces from that procedure are added together. Do not add pieces together from different procedures.
Report all measurements in the units given in the record. Tumor sizes are usually reported in centimeters (cm), but may be reported in millimeters (mm), inches (in. or "), or some other units. If no units are explicitly stated, write "none" in the space provided for "other units."
If the tumor size is reported as "too small to measure" or some similar description, then record the exact words of the description in the units blank of the "other" category.
Enter "x" in blanks that do not apply. For example, a tumor with total diameter reported as 2 cm would be coded xx2.xx. A tumor with total diameter reported as 2.0 cm would be coded xx2.0x.
To convert tumor sizes to comparable units in order to add pieces together or to decide which tumor is largest, use the following conversions: 10 mm = 1 cm; 2.54 cm = 1 inch. Always record the tumor size in the units reported. Record the histology in the pathology report in preference to the medical record if the two disagree.
Record the histology based on the largest tumor specimen, whether from a definitive surgery or from a biopsy.
Histologic grade
DATA ELEMENT: Histologic grade
DEFINITION:
Results of test of growth pattern and features of differentiation. If a tumor grade is specified, but it is not indicated whether it is a histologic or nuclear grade (e.g., "invasive ductal carcinoma, grade I"), assume that it is a histologic grade.
SOURCE DOCUMENT:
Pathology report or medical record. Enter 09 if there is documentation that the test was not performed or if there is no documentation pertaining to histologic grade.
Record the grade based on the pathology report in preference to the medical record if the two disagree.
Record the grade based on definitive surgery in preference to the biopsy, if the two disagree.
The histologic grade should be coded on the basis of the largest specimen when based on biopsy. For example, if an incisional biopsy follows a needle biopsy, the histologic grade should be coded on the basis of the results of the incisional biopsy.
If the histologic grade is given as a range of grades, then code as the highest value in the range.
Definitive surgical procedure
DATA ELEMENT: Definitive surgical procedure.
DEFINITION:
The procedure related to the principal diagnosis or the procedure performed for definitive purposes.
SOURCE DOCUMENT:
Medical record, operative report CODE RANGE: 00 -98
DIRECTIVES: Required
A lumpectomy includes an excisional biopsy and removal of the tumor without the remaining unaffected breast tissue.
A partial / less than total mastectomy includes segemental mastectomy, quadrantectomy, tylectomy, wedge resection, nipple resection, or partial mastectomy NOS.
A subcutaneous mastectomy is the removal of breast tissue without the nipple and areolar complex or overlying skin.
A total or simple mastectomy removes all breast tissue, the nipple and areolar complex. An axillary dissection is not done.
A modified radical mastectomy removes all breast tissue, the nipple, the areolar complex and variable amounts of breast skin and may or may not include a portion of the pectoralis major muscle. The procedure involves an en bloc resection and dissection of the axilla.
A radical mastectomy removes all breast tissue, the nipple, the areolar complex and variable amounts of breast skin, pectoralis major and minor muscles. The procedure involves an en bloc axillary dissection.
An extended radical mastectomy removes all breast tissue, the nipple, the areolar complex and variable amounts of breast skin and pectoralis major and minor muscles. The procedure involves an en bloc axillary dissection and removal of internal mammary nodes.
If a woman participated in a blinded clinical trial involving surgery and the specifics of the type of surgery that she received are unknown then code as 98. 
Date of definitive surgery
DIRECTIVES:
Required. Enter the date of the patient's definitive surgery.
Only enter "default codes" after you have verified that a date is not available. If month is unknown enter MM = 06. If day is unknown enter DD = 15.
Pathology number for surgery
DATA ELEMENT: Pathology number
DEFINITION:
The number from the pathology report of the most definitive surgery SOURCE DOCUMENT: Pathology report CODE RANGE: Numeric
DIRECTIVES:
Report the pathology number recorded on the pathology report associated with the most definitive surgery. Enter 02 if the source document contains a specific indication that a sentinel node evaluation was performed. Enter 02 in preference to 01, even if a full axillary node dissection was performed subsequent to the sentinel node evaluation.
Surgical Margins
Enter 03 if the source document specifically indicates that no axillary node evaluation was performed. Skip to number 3.9.
Enter 04 if the source document contains no mention of axillary node evaluation. Skip to number 3.9Error! Reference source not found..
Axillary status, number of nodes
DATA ELEMENT: Number of regional lymph nodes removed and examined.
DEFINITION:
Number of lymph nodes removed and examined.
SOURCE DOCUMENT: Medical record.
CODE RANGE: 01-99
DIRECTIVES: Required
Record the number of lymph nodes removed and examined by the pathologist. Add together all nodes examined during all breast cancer procedures, including sentinel node evaluation.
If there is documentation that nodes were examined but the exact number is not specified, code "99".
Number of positive nodes
DATA ELEMENT: Number of regional lymph nodes positive DEFINITION: Number of nodes examined that had breast cancer present SOURCE DOCUMENT: Pathology report.
CODE RANGE: 00-99
DIRECTIVES:
Required.
Record the number of lymph nodes that had breast cancer present (positive nodes). Add together the number of positive nodes from all breast cancer procedures, including sentinel node evaluation.
If there is documentation that no nodes were positive, record "00".
If there is documentation that some nodes were positive but the exact number is not specified, record "99". Use the largest tumor piece to determine estrogen receptor status.
Estrogen receptor protein
Code "TEST NOT DONE (DOCUMENTED)" if there is documentation that the test was not performed.
Code "UNKNOWN OR NO INFORMATION" if there is no documentation pertaining to ERP.
Code "POSITIVE TEST RESULTS" if the test is characterized as "FAVORABLE" or "HIGH".
Code "NEGATIVE TEST RESULTS" if the test is characterized as "UNFAVORABLE" or "LOW".
Code "BORDERLINE TEST RESULTS" if the test is characterized as "INTERMEDIATE".
Whether the test is positive, negative or borderline should be based on lab-specific determination of normal range as noted in the laboratory report. Use the largest tumor piece to determine progesterone receptor status.
Progesterone receptor protein
Code "UNKNOWN OR NO INFORMATION" if there is no documentation pertaining to progesterone receptor protein.
Whether the test is positive, negative or borderline should be based on lab-specific determination of normal range as noted in the laboratory report. CODE RANGE: 01 -02
Her2/neu Status
DIRECTIVES:
If there is definite mention that the patient's doctor discussed radiation therapy with her then code 01.
If there is no mention of a discussion between the patient and her doctor about radiation therapy then code as 02. If the patient received a drug not included in the list indicate using the other category and specify the drug. If a patient was enrolled in a clinical trial then specify under other. We will define a recurrence as a tumor that is found after four months of the original diagnosis or through completion of surgery(ies) in first course of treatment, whichever is longer. Do not include ductal carcinoma in-situ or the diagnosis of any other noninvasive tumor as a recurrence
Receipt of radiation treatment
Completion of chemotherapy
Code 01 if there is a definite indication of a breast cancer recurrence. Go to 5.1.1.
If there is no mention that the patient had a recurrence then code 02 and skip to 7. Date of last medical encounter that the patient had with the system.
Side of recurrence
Poor prognosis at last encounter?
DATA 
